Patents by Inventor William E. Yelle

William E. Yelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7098224
    Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: August 29, 2006
    Assignee: Sepracor Inc.
    Inventor: William E. Yelle
  • Patent number: 7030142
    Abstract: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 18, 2006
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Publication number: 20040266792
    Abstract: Methods and compositions utilizing compounds represented by Formula III, 1
    Type: Application
    Filed: July 13, 2004
    Publication date: December 30, 2004
    Applicant: Sepracor Inc.
    Inventor: William E. Yelle
  • Publication number: 20040224989
    Abstract: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also-useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: June 8, 2004
    Publication date: November 11, 2004
    Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
  • Publication number: 20040171647
    Abstract: Methods and compositions are disclosed utilizing optically pure S(−)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(−) isomer is also useful for the treatment of gastroesophageal reflux. S(−)rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 2, 2004
    Applicant: Sepracor Inc.
    Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
  • Publication number: 20040077688
    Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: October 14, 2003
    Publication date: April 22, 2004
    Applicant: SEPRACOR INC.
    Inventor: William E. Yelle
  • Publication number: 20030069280
    Abstract: Methods and compositions are disclosed utilizing optically pure S(−)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(−) isomer is also useful for the treatment of gastroesophageal reflux. S(−)rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: October 2, 2002
    Publication date: April 10, 2003
    Applicant: SEPRACOR INC.
    Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
  • Publication number: 20030008903
    Abstract: Methods and compositions are disclosed utilizing optically pure (+) lansoprazole for the treatment of S ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: August 12, 2002
    Publication date: January 9, 2003
    Applicant: Sepracor Inc.
    Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
  • Patent number: 6500833
    Abstract: Methods and compositions utilizing a compound represented by Formula III, wherein R is chosen from —OH, —P(O)(OH)2 and —SO3H, or pharmaceutically acceptable salts thereof, for the treatment of psychoses in humans are disclosed. The compounds of the present invention exhibit fewer side effects than risperidone, a lessened liability toward drug-drug interactions than risperidone and a more predictable dosing regimen than risperidone. The compounds of the invention are also useful for the treatment of emesis and withdrawal syndromes.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: December 31, 2002
    Assignee: Sepracor Inc.
    Inventor: William E. Yelle
  • Patent number: 6498171
    Abstract: Methods and compositions are disclosed utilizing hydroxyomeprazole for the treatment of ulcers in humans. Hydroxyomeprazole exhibits a lessened liability toward drug-drug interactions than omeprazole and a more predictable dosing regimen than omeprazole. Hydroxyomeprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: December 24, 2002
    Assignee: Sepracor Inc.
    Inventors: William E. Yelle, Dean A. Handley
  • Patent number: 6468997
    Abstract: Methods and compositions are disclosed utilizing N-desmethylolanzapine for the treatment of psychosis in humans. N-Desmethylolanzapine exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. N-Desmethylolanzapine is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: October 22, 2002
    Assignee: Sepracor Inc.
    Inventor: William E. Yelle
  • Patent number: 6465469
    Abstract: The S-isomer of the hydroxy metabolite of nefazodone, S-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. S-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 15, 2002
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Patent number: 6465470
    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: October 15, 2002
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Publication number: 20020115691
    Abstract: Methods and compositions are disclosed utilizing optically pure (−) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: February 25, 2002
    Publication date: August 22, 2002
    Applicant: SEPRACOR INC.
    Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
  • Publication number: 20020099079
    Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: October 19, 2001
    Publication date: July 25, 2002
    Applicant: SEPRACOR INC.
    Inventor: William E. Yelle
  • Publication number: 20020082245
    Abstract: Methods and compositions utilizing compounds represented by Formula III, 1
    Type: Application
    Filed: December 10, 2001
    Publication date: June 27, 2002
    Applicant: Sepracor Inc.
    Inventor: William E. Yelle
  • Publication number: 20020082251
    Abstract: Methods and compositions are disclosed utilizing N-desmethylolanzapine for the treatment of psychosis in humans. N-Desmethylolanzapine exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. N-Desmethylolanzapine is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.
    Type: Application
    Filed: December 19, 2001
    Publication date: June 27, 2002
    Applicant: SEPRACOR INC.
    Inventor: William E. Yelle
  • Publication number: 20020065272
    Abstract: Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. Olanzapine-N-oxide is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.
    Type: Application
    Filed: October 30, 2001
    Publication date: May 30, 2002
    Applicant: SEPRACOR INC.
    Inventor: William E. Yelle
  • Patent number: 6384037
    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: May 7, 2002
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Publication number: 20020052382
    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Application
    Filed: November 19, 2001
    Publication date: May 2, 2002
    Applicant: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle